[1] Siegel R L, Miller K D,Jemal A.Cancer statistics,2020[J].CA Cancer J Clin,2020,70(1):7-30.
[2] Ahmedin J,Rebecca S,Elizabeth W,et a1.Cancer statistics 2007[J].CA Cancer J Clin,2007,57:43-66.
[3] Jemal A, Siegel R, Xu J, et al.. Cancer statistics,2010.CA Cancer J Clin 2010; 60: 277-300.
[4] Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
[5] Perou CM, Sørlie T, Eisen MB,et al. Molecular portraits of human breast tumors. Nature 2000, 406:747–752.
[6] Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869–10874.
[7]Carey LA, Perou CM, Livasy CA,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492–2502.
[8] Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275–1281.
[9] Millar EK, Graham PH, O'Toole SA,et al. Prediction of local recurrence, distant metastases, and death after breast conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009, 27:4701–4708.
[10] Gao J D,Wang J,Zhang B N,et a1.Correlation of pefipheral blood micrometastasis to distant metastasis of breast cancer[J].Chinese Journal of Cancer,2OO7,26(12):1385-1387.
[11] Bundreed NJ. Prognostic and predictive fators in breast cancer [J]. Cancer Treat Rev, 2001, 27(3): 137-142.
[12] Miksicek R J,Myal.Y,Watson P H,et a1.Identification of a noval breast-and salivary gland specific,mucin-like gene strongly expressed in normal and tulnor human mammary epithelium[J].Cancer Res,2002,62(10):2736-2740.
[13] 0’brien N,0’donovan N,Foley D,et a1.Use of a panel of novel genes for diferentiating breast cancer from nonbreasttissues [J].TumorBiol,2007,28:312-317. [14] Skliris GP, Hube F, Gheorghiu I, et, al. Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology. 2008; 52(3):355-369.
[15] Liu ZZ, Xie XD, Qu SX, et a1.Small breast epithelial mucin (SBEM) has the potential to be a marker for predicting hematogenous micrometastasis and response to neoadjuvant chemotherapy in breast cancer. Clinical & Experimental Metastasis, 2010, 27:251-259.
[16] Valladares-ayerbes M, Iglesias-Diaz P, Diaz-Prado S, et al. Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study. J Cancer Res Clin Oncol. 2009 Sep; 135(9):1185-95.
[17] Liang Liu, Zhaozhe Liu , Shuxian Qu, et a1. SBEM tumor tissue expression is associated with increased risk of recurrence in Triple-negative breast cancer patients. Diagnostic Pathology.2013,5(1).
[18] Jennbacken K, Vallbo C, Wang W, et al. Expression of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF Receptor-3 in human prostate cancer are associated with regional lymph node metastasis.Prostate 2005, 65(2):110–116.
[19] Serrero G, Ioffe O. Expression of the novel autocrine growth factor PC-Cell Derived Growth Factor in human breast cancer tissue. Hum Pathol 2003, 34:1148–1154.
[20] Pan AP, Huang GY, Chen J.Relationship between hepatitis B virus covalently closed circular DNA and HBx protein expression in hepatocellular carcinoma and its significance. World Chin J Digestol 2009, 17:712–715.
[21] Serrero G, Hawkins DM, Yue Bet et al.Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma. Breast Cancer Res 2012, 14:R26
[22] Rebecca Siegel, Deepa Naishadham, Ahmedin Jemal. Cancer statistics, 2012. CA:A Cancer Journal for Clinicians 2012, 62(1):10-29.
[23] Wu Fanglan, Fan Chengxian.SBEM mRNA detection and its clinical meaning inbreast cancer patients with bone marrow. Modern Chinese medicine. 2009, 22(19): 3473-3476.
[24] Zhong Lei, Zhang Jianguo, Guo Baoliang, et al. The clinical significance of the peripheral blood expression of SBEM - mRNA and CEA in breast cancer patients.Chinese journal of clinical oncology, 2008,35(23): 1344-1347.
[25] Yang HW, Cao J, Yang NW, et, al. Expression of small breast epithelial mucin mRNA in peripheral blood of breast cancer patients and its clinical significance. Ai Zheng. 2005, 24(7), 842-845.
[26] Ravdin PM, Siminoff LA, et al. Computer program to assist in making decision about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001, 19: 980-991.
[27] Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-Based Validation of thePrognostic Model Adjuvant for early breast cancer. J Clin Oncol 2005, 23: 2716-2725.
[28] Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocrine-Related Cancer 2010, 17: R245-262.
[29] Lindstrom L S,Yau, C,Czene K,et al.Intratumor heterogeneity of the estrogen eceptor and the long-term risk of fatal breast cancer[J].J Natl Cancer Inst, 2018,110(7):726-733.